Certolizumab pegol in treatment of Crohn's disease with perianal lesions

Aim. To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions. Materials and methods. The study included 20 patients with CD with perianal fistulae. Prior to the start of conservative therapy, 7 patients underwent fistulae drainage with setton placement. During the study, all patients received therapy with certolizumab pegol (CP) for a year. At the time of treatment initiation and after 12 months, the CD activity index, the quality of life according to IBDQ questionnaires and the perianal Crohn's disease activity index (PCDAI) were assessed. Results. After a year of CP therapy, clinical remission was achieved in 8 (40%) patients, endoscopic remission in 7 (35%) patients, fistula closure in 6 (30%) patients. There was also a decrease in the PCDAI with the average score 3.6 points compared to 9.3 points (p˂0.05) prior to the treatment. An improvement in the quality of life of patients was also established, the average quality of life index was 182,2 points compared to 156,0 points (p˂0.05) prior to the treatment. Conclusion. This study showed that CP therapy is effective in treatment of CD with perianal lesions

A global perspective on irritable bowel syndrome: a consensus statement of the world gastroenterology organisation summit task force on irritable bowel syndrome

Irritable bowel syndrome (IBS) is common in western Europe and North America, and many aspects of its epidemiology, risk factors, and natural history have been described in these regions. Recent data suggest, however, that IBS is also common in the rest of the world and there has been some evidence to suggest some differences in demographics and presenting features between IBS in the west and as it is experienced elsewhere. The World Gastroenterology Organization, therefore, established a Task Force comprising experts on the topic from all parts of the world to examine IBS from a global perspective. IBS does, indeed, seem to be common worldwide though with some significant variations in prevalence rates between regions and countries and there may well be some potentially interesting variations in presenting symptoms and sex distribution. The global map of IBS is far from complete; community-based prevalence data is not available from many areas. Furthermore, while some general trends are evident in terms of IBS impact and demographics, international comparisons are hampered by differences in diagnostic criteria, study location and methodology; several important unanswered questions have been identified that should form the basis for future collaborative research and have the potential to shed light on this challenging disorder

Иммунотерапия

Руководство написано ведущими иммунологами и врачами разных специализаций, применяющими иммунотерапию в своей практике. В книге рассмотрены принципы иммунотерапии, механизмы действия иммунотропных препаратов и их применение в клинической практике. Описаны иммуноглобулины, пептиды тимуса, цитокины, интерфероны и их индукторы, бактериальные иммуномодуляторы и другие группы препаратов иммунной направленности. Представлены схемы применения иммуномодуляторов и результаты лечения инфекционных заболеваний респираторного и желудочно-кишечного трактов, мочевыделительной и репродуктивной систем, кожи и ее придатков, гепатитов, герпесвирусных инфекций, эндокринных заболеваний, различных видов аллергии. Значительное место уделено иммунотерапии в онкологии. Издание предназначено для врачей различных специальностей: терапевтов, педиатров, хирургов, урологов, дерматологов, микологов, венерологов, онкологов, эндокринологов, инфекционистов, аллергологов-иммунологов